Intuitive Surgical shares traded 3.7% lower at $418.08 at 10:30 a.m. EDT on October 21, 2026, after the robotic-surgery company reported third-quarter revenue of $3.05 billion, up 22%. Procedure volumes and system placements increased, but a $450 million antitrust-settlement charge reduced reported earnings, while management expected full-year da Vinci procedure growth near the midpoint of its 14%–15% range.
Key Takeaways
- Revenue growth outpaced combined da Vinci and Ion procedure growth of approximately 15%.
- The settlement charge pushed GAAP earnings lower, while non-GAAP earnings increased.
- Full-year guidance calls for 14%–15% da Vinci procedure growth and a 68.7%–69.3% non-GAAP gross margin.
Table of Contents
- Intuitive Surgical shares retreat despite higher sales
- Procedure growth supports instruments and accessories sales
- Settlement charge separates reported and adjusted earnings
- Full-year outlook keeps procedure growth near the midpoint
- Conclusion
Intuitive Surgical shares retreat despite higher sales
Intuitive’s third-quarter earnings announcement, released on October 20, covered the three months ended September 30, 2026. Revenue increased from $2.51 billion a year earlier, supported by higher procedure volumes, operating lease revenue and a larger installed base of systems.
The October 21 share price was an intraday observation, not a closing result. The decline followed the earnings release, but the available information does not establish a specific investor motivation or whether results met market expectations.
| Item | Details |
|---|---|
| Da Vinci system placements | 546 in Q3 2026, compared with 427 in Q3 2025. |
| Da Vinci 5 placements | 315, compared with 240 a year earlier. |
| Installed da Vinci base | 12,094 systems at September 30, 2026, up 12% year over year. |
| Ion system placements | 56, compared with 50 a year earlier. |
| Installed Ion base | 1,152 systems at September 30, 2026, up 21% year over year. |
Procedure growth supports instruments and accessories sales
Worldwide da Vinci procedures grew approximately 14% year over year, while Ion procedures increased approximately 31%. Together, the two platforms recorded procedure growth of about 15%.
Instruments and accessories revenue rose 18% to $1.80 billion from $1.52 billion. Intuitive attributed that increase primarily to procedure growth, illustrating why activity on installed systems matters alongside new equipment placements.
Systems revenue increased to $769 million from $590 million, reflecting more da Vinci placements and a larger leased installed base. Of the 546 da Vinci systems placed during the quarter, 291 were under operating leases, including 160 under usage-based arrangements.
Settlement charge separates reported and adjusted earnings
GAAP net income attributable to Intuitive fell to $523 million, or $1.49 per diluted share, from $704 million, or $1.95 per share, a year earlier. The quarter included a $450 million pre-tax antitrust-settlement charge, equivalent to $347 million after tax, or $0.99 per diluted share.
Intuitive reached a written settlement agreement in October without admitting liability or wrongdoing. The agreement includes a one-time payment and injunctive relief, but remains subject to preliminary and final court approval. The recorded charge therefore does not mean the legal process is complete.
Non-GAAP net income increased to $1.05 billion, or $3.00 per diluted share, from $867 million, or $2.40 per share. Both GAAP and non-GAAP earnings included a $22 million after-tax benefit, or $0.06 per share, from refunds of tariffs paid in prior periods.
Full-year outlook keeps procedure growth near the midpoint
Management expects worldwide da Vinci procedure growth of approximately 14%–15% for 2026, closer to the midpoint of that range. This forecast applies to da Vinci procedures alone, rather than the combined da Vinci and Ion growth measure.
The company projects a full-year non-GAAP gross profit margin of 68.7%–69.3% and non-GAAP operating expense growth of 11%–13%. These are management forecasts, not completed results.
The margin range includes an estimated tariff impact equal to 0.9% of revenue, excluding recognized tariff refunds. It assumes tariffs in effect at the time of the release remain in place through year-end; Intuitive warned that additional tariffs could materially affect its results.
Conclusion
Intuitive Surgical’s sales and adjusted earnings grew, while the settlement charge weighed on reported profit. The remaining 2026 results will show where procedure growth and margins land within management’s ranges; court approval of the proposed settlement also remains pending.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
